Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...

3 Reasons Investors Watch United Therapeutics (UTHR) Over the last six months, United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% ...